AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29117738 — intervention group
Group type: COMPARATOR
Intervention: Semi-supervised exercise alone
Number of subjects: 70
Study 28744892 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-theoretic design for phase II trials
Number of subjects: 0
Study 25977408 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mg nicotine lozenges
Number of subjects: 152
Study 25977408 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting support materials and coaching phone calls
Number of subjects: 152
Study 24674975 — intervention group
Group type: EXPERIMENTAL
Intervention: CWI (10.3°C ± 0.2°C)
Number of subjects: 30
Study 24674975 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoneutral water immersion placebo (TWP) (34.7°C ± 0.1°C)
Number of subjects: 30
Study 24674975 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral water immersion control (TWI) (34.7°C ± 0.1°C)
Number of subjects: 30
Study 22543342 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy technique
Number of subjects: 100
Study 22543342 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 20059357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine (TDV), 3 injections at months 0, 4, and 12-15
Number of subjects: 66
Study 20059357 — intervention group
Group type: COMPARATOR
Intervention: Tetravalent dengue vaccine (TDV), 2 injections at months 4 and 12-15
Number of subjects: 66
Study 20059357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine (TDV)
Number of subjects: 66
Study 17278979 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt intake (50 mmol/day)
Number of subjects: 39
Study 15679762 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine pellets (1.5 g/day in three doses)
Number of subjects: 233
Study 15679762 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine tablets (1.5 g/day in three doses)
Number of subjects: 233
Study 12019381 — intervention group
Group type: COMPARATOR
Intervention: Control group (C): All aspirated blood returned into circulation
Number of subjects: 30
Study 12019381 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction blood discarded group (S)
Number of subjects: 30
Study 12019381 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfaces coated with phosphorylcholine group (S+P)
Number of subjects: 30
Study 10225572 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg tablet
Number of subjects: 68
Study 10225572 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/10 mL oral suspension
Number of subjects: 68
Study 10225572 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/10 mL suspension (fasted)
Number of subjects: 68
Study 10225572 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/5 mL suspension (fasted)
Number of subjects: 68
Study 10225572 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/10 mL suspension (fed)
Number of subjects: 68
Study 8846490 — intervention group
Group type: EXPERIMENTAL
Intervention: ParaSight-F test
Number of subjects: 358
Study 2245092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 100
Study 2245092 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen-codeine combination
Number of subjects: 100
Study 639430 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg piretanide
Number of subjects: 8
Study 639430 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg furosemide
Number of subjects: 8
Study 639430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30985725 — intervention group
Group type: EXPERIMENTAL
Intervention: TURP
Number of subjects: 65
Study 30985725 — intervention group
Group type: COMPARATOR
Intervention: HoLEP
Number of subjects: 65
Study 30985725 — intervention group
Group type: EXPERIMENTAL
Intervention: TURP and HoLEP
Number of subjects: 65
Study 29911792 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with Life-Build-Line (LBL) device
Number of subjects: 10
Study 26228672 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 86
Study 26228672 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg
Number of subjects: 86
Study 26228672 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atorvastatin 40 mg and ezetimibe 10 mg
Number of subjects: 86
Study 26228672 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (PS) added to atorvastatin therapy
Number of subjects: 86
Study 26228672 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (PS) added to combined therapy
Number of subjects: 86
Study 22889325 — intervention group
Group type: EXPERIMENTAL
Intervention: Early leakage (EL) diagnosed during initial hospital stay (n = 27)
Number of subjects: 45
Study 22889325 — intervention group
Group type: COMPARATOR
Intervention: Late leakage (LL) diagnosed after hospital discharge (n = 18)
Number of subjects: 45
Study 22428512 — intervention group
Group type: EXPERIMENTAL
Intervention: Perimenopausal Exercise Group (PEMEG)
Number of subjects: 175
Study 22428512 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal Exercise Group (POMEG)
Number of subjects: 175
Study 22428512 — intervention group
Group type: COMPARATOR
Intervention: Perimenopausal Control Group (PEMCG)
Number of subjects: 175
Study 22428512 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal Control Group (POMCG)
Number of subjects: 175
Study 20046230 — intervention group
Group type: EXPERIMENTAL
Intervention: Single antiplatelet therapy (aspirin 100 mg)
Number of subjects: 20
Study 20046230 — intervention group
Group type: COMPARATOR
Intervention: Combination of antiplatelet and anticoagulation therapy (target INR: 2.0‐3.0; mean 2.4+/‐0.3)
Number of subjects: 20
Study 20046230 — intervention group
Group type: COMPARATOR
Intervention: Single antiplatelet therapy (aspirin)
Number of subjects: 20
Study 20046230 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 20
Study 16648530 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing/CBT
Number of subjects: 130
Study 16648530 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 130
Study 15547065 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy computer users with refractive errors
Number of subjects: 10202
Study 15547065 — intervention group
Group type: COMPARATOR
Intervention: Subjects without refractive errors
Number of subjects: 10202
Study 11405833 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity laser treatment
Number of subjects: 53
Study 11405833 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity laser treatment
Number of subjects: 53
Study 9210608 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of terlipressin (1-2 mg, i.v. bolus) with ANP (35 ng/kg, i.v. bolus followed by 15 ng x kg(‐1) x min(‐1) for 60 min)
Number of subjects: 16
Study 9210608 — intervention group
Group type: COMPARATOR
Intervention: Terlipressin alone (1-2 mg, i.v. bolus)
Number of subjects: 16
Study 7957341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus Cyclophosphamide (PC)
Number of subjects: 0
Study 7957341 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC (Cisplatin plus Cyclophosphamide)
Number of subjects: 0
Study 7957341 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (after PAC or CAC therapy)
Number of subjects: 0
Study 7957341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 0
Study 7957341 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 0
Study 3659136 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone spinal extension exercise, 20 repetitions each day for four weeks.
Number of subjects: 36
Study 3659136 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise).
Number of subjects: 36
Study 31366649 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored rehabilitation programme
Number of subjects: 0
Study 31366649 — intervention group
Group type: COMPARATOR
Intervention: Standardised strengthening programme
Number of subjects: 0
Study 29333870 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (bike/cross-trainer/brisk walking for 45 minutes, three times/week)
Number of subjects: 52
Study 29333870 — intervention group
Group type: COMPARATOR
Intervention: Control (usual daily activities)
Number of subjects: 52
Study 26691222 — intervention group
Group type: EXPERIMENTAL
Intervention: Debulking surgery (DS) with complete macroscopic resection (RD0)
Number of subjects: 326
Study 26691222 — intervention group
Group type: EXPERIMENTAL
Intervention: Debulking surgery (DS) with residual disease of 1-10mm (RD1-10)
Number of subjects: 326
Study 26691222 — intervention group
Group type: EXPERIMENTAL
Intervention: Debulking surgery (DS) with residual disease of >10mm (RD>10)
Number of subjects: 326
Study 26691222 — intervention group
Group type: COMPARATOR
Intervention: No surgery (NoCS)
Number of subjects: 326
Study 24613373 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfixing technique
Number of subjects: 126
Study 24613373 — intervention group
Group type: COMPARATOR
Intervention: Single wall technique
Number of subjects: 126
Study 22682723 — intervention group
Group type: EXPERIMENTAL
Intervention: 24/4 regimen (20 mcg ethinyl estradiol and 1 mg norethindrone acetate)
Number of subjects: 18
Study 22682723 — intervention group
Group type: COMPARATOR
Intervention: 21/7 regimen (20 mcg ethinyl estradiol and 1 mg norethindrone acetate)
Number of subjects: 18
Study 22682723 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (24/4 and 21/7)
Number of subjects: 18
Study 20697079 — intervention group
Group type: EXPERIMENTAL
Intervention: p16-positive tumors
Number of subjects: 185
Study 20697079 — intervention group
Group type: EXPERIMENTAL
Intervention: p16-positive patients
Number of subjects: 185
Study 20697079 — intervention group
Group type: COMPARATOR
Intervention: tirapazamine arm
Number of subjects: 185
Study 18816238 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentrations of total omega‐3 fatty acids, eicosapentaenoic and docosahexaenoic acids in red blood cells, and ornithine in plasma
Number of subjects: 54
Study 18816238 — intervention group
Group type: EXPERIMENTAL
Intervention: High total omega‐6 fatty acids
Number of subjects: 54
Study 18816238 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of docosahexaenoic acid, ornithine, and omega‐3 index; high total omega‐6 and omega‐3/omega‐6 ratios
Number of subjects: 54
Study 18816238 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of ornithine
Number of subjects: 54
Study 18816238 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak concentrations of fatty acids in red blood cells
Number of subjects: 54
Study 18816238 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of arginine
Number of subjects: 54
Study 15593189 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC‐28326 40 mg
Number of subjects: 13
Study 15593189 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC‐28326 10 mg
Number of subjects: 13
Study 15593189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 11340365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal CCK-8
Number of subjects: 0
Study 11340365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9175051 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialyser containing PMMA membrane
Number of subjects: 0
Study 9175051 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialyser containing Gambrane membrane
Number of subjects: 0
Study 9175051 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialyser containing Cuprophan membrane
Number of subjects: 0
Study 9175051 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysers containing Cuprophan and Gambrane membranes
Number of subjects: 0
Study 9175051 — intervention group
Group type: COMPARATOR
Intervention: All dialysers
Number of subjects: 0
Study 7898992 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthetic information during practice trials
Number of subjects: 20
Study 7898992 — intervention group
Group type: COMPARATOR
Intervention: No kinesthetic information during practice trials
Number of subjects: 20
Study 3036715 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg five times daily) for seven days
Number of subjects: 56
Study 3036715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (10 mg/kg three times daily) combined with prednisolone (0.7 mg/kg daily) for ten days
Number of subjects: 56
Study 30613057 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated physical activity program (INT) - 12 weeks duration, including self-regulation, support, and policy-environmental strategies
Number of subjects: 268
Study 30613057 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated physical activity program (INT) - 12 weeks duration
Number of subjects: 268
Study 30613057 — intervention group
Group type: COMPARATOR
Intervention: Control group (CT) - no strategies received
Number of subjects: 268
Study 30613057 — intervention group
Group type: EXPERIMENTAL
Intervention: Education group (ED) - self-regulation strategies only
Number of subjects: 268
Study 27005766 — intervention group
Group type: EXPERIMENTAL
Intervention: TABLETS intervention
Number of subjects: 60
Study 27005766 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 24748531 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + CHO (6 mg kg(-1) BW caffeine and 0.8 g kg(-1) BW carbohydrate)
Number of subjects: 12
Study 24748531 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 12
Study 23876565 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupping therapy
Number of subjects: 200
Study 20592124 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal coordinates during saccade planning
Number of subjects: 18
Study 20592124 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal coordinates during sensory processing
Number of subjects: 18
Study 20592124 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal coordinates during saccade execution
Number of subjects: 18
Study 20592124 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonretinal coding
Number of subjects: 18
Study 20592124 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral bias of activation in IPS and FEF
Number of subjects: 18
Study 20592124 — intervention group
Group type: EXPERIMENTAL
Intervention: SEF
Number of subjects: 18
Study 17936025 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tension measured using surface electromyography in the positive position of the O'Brien test.
Number of subjects: 17
Study 17936025 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive tension measured using a load cell in the negative position of the O'Brien test.
Number of subjects: 17
Study 17936025 — intervention group
Group type: COMPARATOR
Intervention: O'Brien test (both positions).
Number of subjects: 17
Study 17012983 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (mean maximum dosage 862.50±279.19 mg/day)
Number of subjects: 20
Study 17012983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 14610141 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual assistance
Number of subjects: 0
Study 14610141 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation‐exsufflation
Number of subjects: 0
Study 11060815 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal ziconotide
Number of subjects: 0
Study 8765075 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoechoic ventral embryologic cephalic pancreas
Number of subjects: 446
Study 8765075 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive group (hypoechoic pancreas)
Number of subjects: 446
Study 8765075 — intervention group
Group type: COMPARATOR
Intervention: Negative group (reference)
Number of subjects: 446
Study 8765075 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pancreatic echogenicity
Number of subjects: 446
Study 8765075 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex ratio of hypoechoic pancreas
Number of subjects: 446
Study 1557976 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial uncertainty effect in stereoacuity tests
Number of subjects: 0
Study 1557976 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal uncertainty effect in stereoacuity tests
Number of subjects: 0
Study 3901208 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 20
Study 3901208 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 20
Study 31706345 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (twice per week for 12 sessions at specified acupoints)
Number of subjects: 320
Study 31706345 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 320
Study 29743825 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine-electrolyte (CE) supplementation
Number of subjects: 23
Study 29743825 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) group
Number of subjects: 23
Study 27238898 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-size enriched beef meal
Number of subjects: 120
Study 27238898 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-size enriched chicken meal
Number of subjects: 120
Study 27238898 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched meals (both normal and reduced size)
Number of subjects: 120
Study 27238898 — intervention group
Group type: COMPARATOR
Intervention: Normal-size meals
Number of subjects: 120
Study 27238898 — intervention group
Group type: COMPARATOR
Intervention: Reduced-size meals
Number of subjects: 120
Study 25275577 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine (bolus 1.5 mg/kg at induction, then infusion at 2 mg/kg/h, stopped 2 hours after surgery)
Number of subjects: 71
Study 25275577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 22541418 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal triple antiretroviral
Number of subjects: 2369
Study 22541418 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily infant nevirapine
Number of subjects: 2369
Study 22541418 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2369
Study 19915017 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d)
Number of subjects: 78
Study 19915017 — intervention group
Group type: COMPARATOR
Intervention: Metformin (2000 mg/d)
Number of subjects: 78
Study 17878815 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 12934987 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-loaded divalproex (20 or 30 mg/kg/day on days 1 and 2 followed by 20 mg/kg/day)
Number of subjects: 348
Study 12934987 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-loaded divalproex
Number of subjects: 348
Study 12934987 — intervention group
Group type: COMPARATOR
Intervention: Standard-titration divalproex
Number of subjects: 348
Study 12934987 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 348
Study 12934987 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 348
Study 12934987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 10729387 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous wildtype LL/QQ genotype of PON1
Number of subjects: 186
Study 10729387 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 186
Study 10729387 — intervention group
Group type: EXPERIMENTAL
Intervention: Total plasma cholesterol
Number of subjects: 186
Study 10729387 — intervention group
Group type: EXPERIMENTAL
Intervention: LL/QQ genotype of PON1
Number of subjects: 186
Study 8602748 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants (international normalized ratio range, 2.8-4.8)
Number of subjects: 3404
Study 8602748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3404
Study 1394813 — intervention group
Group type: EXPERIMENTAL
Intervention: Early instillation of Adriamycin alone (Group A)
Number of subjects: 275
Study 1394813 — intervention group
Group type: EXPERIMENTAL
Intervention: Early instillation of Adriamycin with oral administration of 5-fluorouracil (Group B)
Number of subjects: 275
Study 1394813 — intervention group
Group type: COMPARATOR
Intervention: Delayed instillation of Adriamycin alone (Group C)
Number of subjects: 275
Study 1394813 — intervention group
Group type: COMPARATOR
Intervention: Delayed instillation of Adriamycin with oral administration of 5-fluorouracil (Group D)
Number of subjects: 275
Study 2983151 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy and oral Levamisole
Number of subjects: 25
Study 2983151 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy only
Number of subjects: 25
Study 31061511 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic spinal adjustment
Number of subjects: 15
Study 31061511 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 15
Study 28627930 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 100 mg
Number of subjects: 60
Study 28627930 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 60
Study 25864750 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis of the Chinese drug
Number of subjects: 296
Study 25864750 — intervention group
Group type: COMPARATOR
Intervention: Medium frequency electrotherapy
Number of subjects: 296
Study 23524368 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured injury prevention program performed twice weekly for the entirety of the season (58 prevention sessions)
Number of subjects: 49
Study 23524368 — intervention group
Group type: COMPARATOR
Intervention: Control season (2009‐2010)
Number of subjects: 49
Study 23524368 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention season (2008‐2009)
Number of subjects: 49
Study 21778313 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense chemotherapy
Number of subjects: 147
Study 21778313 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 147
Study 19636320 — intervention group
Group type: EXPERIMENTAL
Intervention: Light intensity resistance exercise training (3 times per week, 35-40 min per session)
Number of subjects: 160
Study 19636320 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 160